Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with XXXX for peritoneal @entity2615 : Preliminary results and survival analysis.

@entity901 @entity1 @entity2615 @entity1358 @entity395 @entity1104
BACKGROUND: Peritoneal @entity2615 is a @entity395 with poor prognosis. The present study reports single center experience with @entity1104 ( @entity1104 ) and hyperthermic intraperitoneal chemotherapy with @entity901 (HIPEC-OX) over an eight-year period. METHODS: Prospectively collected data of all consecutive @entity1 with epithelial or multicystic peritoneal @entity2615 from August 2004 to October 2012 was analyzed. @entity1 with @entity1358 or biphasic peritoneal @entity2615 were not included due to general poor prognosis. Treatment consisted in @entity1104 and HIPEC-OX (460  mg/m(2)) at 43    C during 30  min. For statistical analysis, Kaplan-Meier survival curves were plotted and compared using log-rank tests. Cox proportional-hazards regression model was used to analyze the influence of different variables on survival. RESULTS: Nineteen @entity1 with peritoneal @entity2615 underwent laparotomy with @entity1104 and HIPEC-OX with curative intent (15 epithelial, and 4 multicystic). Mean follow-up was 36.7 months. The estimated one-year and three-year overall survival rates were respectively 100% and 91%. The estimated one-year and three-year disease-free survival rates were respectively 77% and 50%. Complications were graded according to the Clavien-Dindo classification [1] and major complications occurred in 57% of cases. There was no postoperative mortality. Histological grade was not a prognostic factor of disease-free survival (p  =  0.37). CONCLUSION: When comparing survival results as well as morbidity-mortality rates, the present study shows that @entity1104 and HIPEC-OX is a valid treatment for peritoneal @entity2615 .
